Scholarlink

Purpose <p>This study evaluated the safety and preliminary efficacy of zolbetuximab plus chemotherapy in patients with claudin 18 isoform 2 (CLDN18.2)-positive advanced gastric cancer (AGC).</p> Methods <p>This single-institutional retrospective study enrolled patients with HER2-negative CLDN18.2-positive AGC who were treated with zolbetuximab plus chemotherapy between July 2024 and August 2025.</p> Results <p>The cohort included 50 patients with a median age of 63&#xa0;years (range 30–83; 44% male). The primary tumor location was the stomach in 86% of the patients. Meanwhile, 26% of the patients underwent prior gastrectomy. The PD-L1 combined positive score was &lt; 5 in 87% of patients. Among 24 patients with measurable lesions at baseline, the objective response and disease control rates were 66.7% and 87.5%, respectively. After median follow-up of 7.3&#xa0;months, median progression-free survival and the duration of response were 6.7 [95% confidence interval (CI) 5.3–10.7] and 6.7&#xa0;months (95% CI 4.7–10.2), respectively. Grade ≥ 3 treatment-emergent adverse events occurred in 62% of the patients, most commonly hypoalbuminemia (22%), neutrophil count decreased (22%) and anorexia (12%). Subsequent treatment was received by 83% of the patients.</p> Conclusions <p>Zolbetuximab plus chemotherapy was administered to real-world patients with CLDN18.2-positive AGC with acceptable safety profiles and showed preliminary antitumor efficacy. Nevertheless, some adverse events warrant careful monitoring.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and efficacy of zolbetuximab plus chemotherapy for claudin 18 isoform 2-positive advanced gastric cancer: initial report of real-world experience

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月18日

查看全文
  • Keitaro Shimozaki,
  • Akira Ooki,
  • Shota Fukuoka,
  • Hiroki Osumi,
  • Kaoru Yoshikawa,
  • Koichiro Yoshino,
  • Shohei Udagawa,
  • Takeru Wakatsuki,
  • Eiji Shinozaki,
  • Mariko Ogura,
  • Keisho Chin,
  • Kensei Yamaguchi

摘要

Purpose

This study evaluated the safety and preliminary efficacy of zolbetuximab plus chemotherapy in patients with claudin 18 isoform 2 (CLDN18.2)-positive advanced gastric cancer (AGC).

Methods

This single-institutional retrospective study enrolled patients with HER2-negative CLDN18.2-positive AGC who were treated with zolbetuximab plus chemotherapy between July 2024 and August 2025.

Results

The cohort included 50 patients with a median age of 63 years (range 30–83; 44% male). The primary tumor location was the stomach in 86% of the patients. Meanwhile, 26% of the patients underwent prior gastrectomy. The PD-L1 combined positive score was < 5 in 87% of patients. Among 24 patients with measurable lesions at baseline, the objective response and disease control rates were 66.7% and 87.5%, respectively. After median follow-up of 7.3 months, median progression-free survival and the duration of response were 6.7 [95% confidence interval (CI) 5.3–10.7] and 6.7 months (95% CI 4.7–10.2), respectively. Grade ≥ 3 treatment-emergent adverse events occurred in 62% of the patients, most commonly hypoalbuminemia (22%), neutrophil count decreased (22%) and anorexia (12%). Subsequent treatment was received by 83% of the patients.

Conclusions

Zolbetuximab plus chemotherapy was administered to real-world patients with CLDN18.2-positive AGC with acceptable safety profiles and showed preliminary antitumor efficacy. Nevertheless, some adverse events warrant careful monitoring.